CA Patent

CA2556214A1 — Combination of an nmda receptor antagonist and an anti-epileptic drug for the treatment of epilepsy and other cns disorders

Assigned to Adamas Pharmaceuticals Inc · Expires 2005-09-01 · 21y expired

What this patent protects

The present invention relates to methods and compositions for treating CNS-related disorders.

USPTO Abstract

The present invention relates to methods and compositions for treating CNS-related disorders.

Drugs covered by this patent

Patent Metadata

Patent number: CA2556214A1
Jurisdiction: CA
Classification: —
Expires: 2005-09-01
Drug substance claim: No
Drug product claim: No
Assignee: Adamas Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.